首页> 美国卫生研究院文献>Frontiers in Chemistry >Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples
【2h】

Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples

机译:对映体的合成,手性分离和四种吲哚-3-羧酰胺型合成大麻素受体激动剂的生物活性及其在缉获药物样品中的检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Synthetic cannabinoid receptor agonists (SCRAs) have been the largest group of illicit psychoactive substances reported to international monitoring and early warning systems for many years. Carboxamide-type SCRAs are amongst the most prevalent and potent. Enantiospecific synthesis and characterization of four indazole-3-carboxamides, AMB-FUBINACA, AB-FUBINACA, 5F-MDMB-PINACA (5F-ADB), and AB-CHMINACA is reported. The interactions of the compounds with CB1 and CB2 receptors were investigated using a G-protein coupled receptor (GPCR) activation assay based on functional complementation of a split NanoLuc luciferase and EC50 (a measure of potency) and Emax (a measure of efficacy) values determined. All compounds demonstrated higher potency at the CB2 receptor than at the CB1 receptor and (S)-enantiomers had an enhanced potency to both receptors over the (R)-enantiomers. The relative potency of the enantiomers to the CB2 receptor is affected by structural features. The difference was more pronounced for compounds with an amine moiety (AB-FUBINACA and AB-CHMINACA) than those with an ester moiety (AMB-FUBINACA and 5F-MDMB-PINACA). An HPLC method was developed to determine the prevalence of (R)-enantiomers in seized samples. Lux® Amylose-1 [Amylose tris(3,5-dimethylphenylcarbamate)] has the greatest selectivity for the SCRAs with a terminal methyl ester moiety and a Lux® i-Cellulose-5 column for SCRAs with a terminal amide moiety. Optimized isocratic separation methods yielded enantiomer resolution values (Rs) ≥ 1.99. Achiral GC-MS analysis of seized herbal materials (n = 16), found 5F-MDMB-PINACA (<1.0–91.5 mg/g herbal material) and AMB-FUBINACA (15.5–58.5 mg/g herbal material), respectively. EMB-FUBINACA, AMB-CHMICA, 5F-ADB-PINACA isomer 2, and ADB-CHMINACA were also tentatively identified. Analysis using chiral chromatography coupled to photodiode array and quadrupole time of flight mass spectrometry (chiral HPLC-PDA-QToF-MS/MS) confirmed that the (S)-enantiomer predominated in all samples (93.6–99.3% (S)-enantiomer). Small but significant differences in synthesis precursor enantiopurity may provide significant differences between synthesis batches or suppliers and warrants further study. A method to compare potency between samples containing different SCRAs at varying concentrations was developed and applied in this small preliminary study. A 10-fold difference in the “intrinsic” potency of samples in the study was noted. With the known heterogeneity of SCRA infused materials, the approach provides a simplified method for assessing and communicating the risk of their use.
机译:合成大麻素受体激动剂(SCRA)多年来一直是国际监测和预警系统报告的最大的非法精神活性物质。羧酰胺型SCRA是最普遍和有效的。据报导了四种吲唑-3-甲酰胺,AMB-FUBINACA,AB-FUBINACA,5F-MDMB-PINACA(5F-ADB)和AB-CHMINACA的对映体合成和表征。使用G蛋白偶联受体(GPCR)活化测定法研究化合物与CB1和CB2受体的相互作用,该测定基于拆分的NanoLuc荧光素酶的功能互补和EC50(效力的量度)和Emax(效力的量度)值决心。所有化合物对CB2受体的效力均高于对CB1受体的效力,并且(S)-对映体对两种受体的效力均高于(R)-对映体。对映异构体对CB2受体的相对效能受结构特征的影响。对于具有胺部分的化合物(AB-FUBINACA和AB-CHMINACA),其差异比具有酯部分的化合物(AMB-FUBINACA和5F-MDMB-PINACA)更为明显。开发了一种HPLC方法来确定缉获样品中(R)-对映异构体的普遍性。 Lux®直链淀粉-1 [直链淀粉三(3,5-二甲基苯基氨基甲酸酯)]对具有末端甲酯基团的SCRA具有最大的选择性,对于具有末端酰胺基团的SCRA具有Lux-i-Cellulose-5色谱柱。优化的等度分离方法可得到对映体拆分值(Rs)≥1.99。缉获的草药材料的手性GC-MS分析(n = 16),分别发现5F-MDMB-PINACA(<1.0-91.5 mg / g草药材料)和AMB-FUBINACA(15.5-58.5 mg / g草药材料)。还初步确定了EMB-FUBINACA,AMB-CHMICA,5F-ADB-PINACA异构体2和ADB-CHMINACA。使用与光电二极管阵列和四极杆飞行时间质谱联用的手性色谱分析(手性HPLC-PDA-QToF-MS / MS)证实,所有样品中(S)-对映异构体占主导地位(93.6–99.3%(S)-对映异构体) 。合成前体对映体纯度的微小差异但可能存在重大差异,可能在合成批次或供应商之间产生重大差异,有待进一步研究。在这个小型的初步研究中,开发了一种比较包含不同浓度的不同SCRA的样品之间效价的方法,并将其应用。在该研究中,样本的“内在”效力相差10倍。凭借已知的SCRA灌注材料的异质性,该方法为评估和传达其使用风险提供了一种简化的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号